Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gill Mundin

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Expert Opinion on Investigational Drugs|March 15, 2011
Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteersKevin Smith, Michael Hopp, Gill Mundin, et al.
Scientific Reports|October 8, 2024
Named entity recognition of pharmacokinetic parameters in the scientific literatureFerran Gonzalez Hernandez, Quang Nguyen, Victoria C Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2023
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1Anna D Staniszewska, Domenic Pilger, Sonja J Gill, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Expert Opinion on Investigational Drugs|March 15, 2011
Naloxone as part of a prolonged release oxycodone/naloxone combination reduces oxycodone-induced slowing of gastrointestinal transit in healthy volunteersKevin Smith, Michael Hopp, Gill Mundin, et al.
Scientific Reports|October 8, 2024
Named entity recognition of pharmacokinetic parameters in the scientific literatureFerran Gonzalez Hernandez, Quang Nguyen, Victoria C Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2023
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1Anna D Staniszewska, Domenic Pilger, Sonja J Gill, et al.
Pageof 2